{"podcast":{"title":"BioTalk Unzipped","slug":"biotalk-unzipped-6702602","podcast_index_feed_id":6702602,"rss_url":"https://feeds.captivate.fm/biotalk-unzipped/","website_url":"https://www.biotalkunzipped.com","image_url":"https://artwork.captivate.fm/bc8c17ac-b08b-4ac4-b89d-c3f29318523c/updated-BioTalk-Logo.png","author":"Gregory Austin","episode_count":43,"summary":"BioTalk Unzipped, hosted by Gregory Austin and Dr. Chad Briscoe, unzips the stories behind medical progress through candid, intelligent, and often entertaining conversations with leaders across biotechnology, pharmaceuticals, medical technology, clinical research, bioanalysis, and drug development. Each episode explores the science, strategy, setbacks, breakthroughs, and human stories shaping the future of medicine. From first-in-human trials and biomarkers to oncology, rare disease, AI, regulatory strategy, and emerging therapeutic technologies, BioTalk Unzipped makes complex life science topics engaging, accessible, and relevant. The show feels like the conversation you would want to overhear after a great scientific conference: thoughtful, unscripted, curious, and grounded in real-world experience. We bring listeners inside the decisions, discoveries, and personal journeys behind the therapies and technologies that may one day reduce suffering and improve lives.","last_synced_at":"2026-06-12T10:17:58.642598+00:00","page_url":"https://stenobird.com/podcast/biotalk-unzipped-6702602"},"episode":{"title":"Long-acting Cell-Based Gene Therapy, Fabry Disease and Beyond with Glafabra CEO, Dr. Chris Hopkins","slug":"long-acting-cell-based-gene-therapy-fabry-disease-and-beyond-with-glafabra-ceo-dr-chris-hopkins","published_at":"2025-12-22T16:47:00+00:00","page_url":"https://stenobird.com/podcast/biotalk-unzipped-6702602/long-acting-cell-based-gene-therapy-fabry-disease-and-beyond-with-glafabra-ceo-dr-chris-hopkins","show_page_url":"https://stenobird.com/podcast/biotalk-unzipped-6702602","url":"https://biotalk-unzipped.captivate.fm/episode/dr-hopkins-glafabra-genetherapy","audio_url":"https://episodes.captivate.fm/episode/c43407d2-c5c6-45de-9e45-73283b4b3e74.mp3","summary":"In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and biotech entrepreneur, to explore the science and strategy behind next generation cell-based gene therapies for rare diseases. With more than 25 years of experience spanning gene augmentation, rare disease biology, CRISPR licensing, and biotech formation, Dr. Hopkins shares how autologous, ex vivo engineered cell therapies may overcome key limitations of current enzyme replacement and viral gene therapies, particularly for Fabry disease. The conversation dives deep into: • How lentiviral gene augmentation in patient derived cells enables sustained enzyme production • Why redosing matters and where one time AAV therapies fall short • The scientific rationale for early intervention, including potential newborn treatment • Differences between autologous and emerging allogeneic approaches • Regulatory pathways for rare disease therapies and recent FDA developments • The role of non animal models in translational research • Montana’s early access therapy law and its broader implications • Building biotech platforms amid a challenging funding environment Topics include cell based gene therapy, Fabry disease, lentiviral vectors, stem cell engineering, rare disease drug development, regulatory science, and translational medicine. Subscribe to BioTalk Unzipped for in depth conversations with the scientists and leaders shaping the future of biomedical innovation. 00:00 - Intro 00:53 – Welcome to BioTalk Unzipped, Guest intro: Dr. Chris Hopkins 02:10 – Guest charity: Environmental Defense Fund 03:12 – His journey into rare-disease therapeutics and Glafabra 05:58 – Discovering a new enzyme-deficiency therapy 06:39 – Current standa…","meta_description":"In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2940,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biotalk-unzipped-6702602/episodes/long-acting-cell-based-gene-therapy-fabry-disease-and-beyond-with-glafabra-ceo-dr-chris-hopkins/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biotalk-unzipped-6702602/long-acting-cell-based-gene-therapy-fabry-disease-and-beyond-with-glafabra-ceo-dr-chris-hopkins.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}